Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.
Advertisement
[the_ad id="32629"]
The role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.
By Editor